Angle PLC Announces ANGLE launch of Portrait Flex assay - Seite 2
ANGLE Founder and Chief Executive, Andrew Newland, added:
"To support adoption of its technology by adding "content", ANGLE has been developing a menu of imaging assays and molecular assays to analyse the CTCs harvested by the Parsortix system. These assays support both ANGLE's pharma services business and product business for third-party customers."
*For Research Use Only. Not For Use in Diagnostic Procedures.
**Analytical sensitivity = Proportions of spiked cells known to express the marker(s) of interest which were marker positive in the assay. Analytical specificity = Proportions of spiked cells known to NOT express the marker(s) of interest which were marker negative in the assay.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations |
|
Berenberg (NOMAD and Joint Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+44 (0) 20 3207 7800 |
Jefferies (Joint Broker) Thomas Bective, Shaam Vora |
+44 (0) 20 7029 8000 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market using a simple blood sample. ANGLE's
FDA cleared and patent protected circulating tumor cell (CTC) harvesting technology known as the Parsortix® system enables complete analysis of the sample including whole cell
imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
Lesen Sie auch
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte